# Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma

> **NCT01497275** · PHASE2 · TERMINATED · sponsor: **Duke University** · enrollment: 5 (actual)

## Conditions studied

- Mantle-Cell Lymphoma

## Interventions

- **DRUG:** Rituximab, Bortezomib,Y90 ibritumomab tiuxetan

## Key facts

- **NCT ID:** NCT01497275
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-02
- **Primary completion:** 2014-05
- **Final completion:** 2014-05
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Low accrual due to the approval of new drugs for use in Mantle cell lymphoma.
- **Last updated:** 2015-07-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01497275

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01497275, "Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01497275. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*